A. Delacrétaz

Discipline

Psychologie (4) Education (1)

Type de document

Articles (22) Autres (1)

Co-auteur

Date

Source

Mot-clé

Patients (18) Patients (18) Treatment (17) risque (13) Risk (13) Psychotropic drugs (13) Weight gain (12) Population (12) Human beings (12) Population (12) poids (11) Body mass index (11) Weight (11) association (10) âge (10) adulte (10) Social groups (10) Psychotherapy patients (10) Older people (10) Age (10) Age (10) adulte (10) Months (9) cohorte (9) santé (8) Obesity (8) Health (8) Health (8) Swiss (7) Psychiatry (7)

Documents écrit par A. Delacrétaz (22) | parle de A. Delacrétaz (0)

Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
J. Sjaarda et al.
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.
B.I. Perry et al.
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
N. Laaboub et al. (17 mai 2022)
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
C. Dubath et al. (7 oct. 2021)
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population.
A. Delacrétaz et al.
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
C. Dubath et al. (26 juin 2021)
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.
N. Laaboub et al. (2021)
Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland.
C. Dubath et al. (31 mars 2020)
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.
A. Glatard et al.
Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication.
L. Alameda et al. (2020)
Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients.
A. Delacrétaz et al. (26 déc. 2019)
Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.
A. Delacrétaz et al. (9 avr. 2019)
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.
A. Delacrétaz et al. (2018)
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs.
A. Delacrétaz et al.
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.
A. Delacrétaz et al. (10 sept. 2017)
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
F. Vandenberghe et al.
Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.
L. Quteineh et al. (1 juil. 2016)
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts.
N. Saigi-Morgui et al. (2016)
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments.
N. Saigi-Morgui et al. (2015)
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.
A. Delacrétaz et al. (2015)
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments.
L. Quteineh et al. (2015)
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
F. Vandenberghe et al. (2015)